Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced the launch of a new sub-brand, RenBiologics?, to represent the company?s antibody discovery business division. RenBiologics business will cover out-licensing/co-development of the company?s extensive library of fully human antibodies, as well as licensing of RenMice®, the company?s fully human antibody/TCR discovery platforms. The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company?s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Equities
2315
CNE100005D27
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.89 CNY | +1.95% | -7.01% | -25.79% |
May. 06 | Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies | CI |
Apr. 26 | Biocytogen Pharmaceuticals' Loss Narrows in 2023 | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.79% | 454M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- 2315 Stock
- News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics